Company Details

Codex Genetics uses the power of genomic sequencing to help people understand, manage, and treat diseases. It provides holistic, clinically actionable disease management solutions to patients. Codex has developed the CoGenesis® Cancer and CoGenesis® Neuro genetic test using next sequencing technology. CoGenesis® Cancer detects 9 types of cancer and aberrations in 523 cancer genes in just one test, and CoGenesis® Neuro helps shorten the diagnostic time of neurodegenerative disease from up to 20 years, to just 6 weeks. Codex Genetics also creates a bioinformatics system for medical professionals. CoGenesis® Bioinformatics is a data-driven, customisable platform that provides analysis for diagnosing and treating cancer and rare diseases. Through AI-powered analytics on both genetic and clinic data, Codex provides professional genetic data analysis to hospitals, biopharma, clinical research centres and universities.

CoGenesis® Cancer detects 9 types of cancer and aberrations in 523 cancer genes in just one test, and CoGenesis® Neuro helps shorten the diagnostic time of neurodegenerative disease from up to 20 years, to just 6 weeks. By coupling genomics profiling and targeted therapies, such "precision medicine" approach could bring less side effects and more effective than the traditional approach which mainly based on the use of cytotoxic therapies.